Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
Metrics: PDF 1444 views | HTML 3656 views | ?
Yu Liu1,2, Wen-zhu Wan1, Yan Li1, Guan-lian Zhou1 and Xin-guang Liu2
1 School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, Jinan, P. R. China
2 Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China
Xin-guang Liu, email:
Keywords: phosphatidylinostitol-3-kinase; PI3K; inhibitor; mTOR pathway; anticancer
Received: August 15, 2016 Accepted: October 04, 2016 Published: October 18, 2016
Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/ mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.